loading page

Are Aortic Surgery Device Technology Providers Valid or Valued Assets?
  • Cian Tan,
  • Mohammed Idhrees,
  • Mohamad Bashir
Cian Tan
Queen Mary University of London Barts and The London School of Medicine and Dentistry

Corresponding Author:[email protected]

Author Profile
Mohammed Idhrees
SRM Institutes for Medical Science Vadapalani
Author Profile
Mohamad Bashir
SRM Institutes for Medical Science Vadapalani
Author Profile


ABSTRACT The involvement of Medical Technology (MedTech) corporations in the provision of surgical care remains a topic of debate. This relationship is especially relevant in cardiac and aortic surgery as the use of grafts, stents, prostheses, and other devices is an integral component of most procedures. Many argue that the involvement of device representatives in cardiac surgical cases is valuable – they are often experts on their product and are able to contribute their expertise in challenging cases. Yet, the potential for MedTech corporations to influence surgeons’ clinical decision-making introduces a conflict-of-interest and calls into question what the ‘best practice’ for sales reps should be. The influence of MedTech corporations over policymaking bodies in the US, UK, and Europe also represents a major issue for transparency and is equally deserving of evaluation.
28 Aug 2021Submitted to Journal of Cardiac Surgery
28 Aug 2021Submission Checks Completed
28 Aug 2021Assigned to Editor
28 Aug 2021Reviewer(s) Assigned
02 Sep 2021Review(s) Completed, Editorial Evaluation Pending
02 Sep 2021Editorial Decision: Accept
Dec 2021Published in Journal of Cardiac Surgery volume 36 issue 12 on pages 4453-4455. 10.1111/jocs.15993